Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Carboplatin + Durvalumab + Etoposide|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Carboplatin||Paraplatin||CBDCA||Chemotherapy - Platinum 7||Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary).|
|Durvalumab||Imfinzi||MEDI4736||Immune Checkpoint Inhibitor 148 PD-L1/PD-1 antibody 93||Imfinzi (durvalumab) is a monoclonal antibody that binds to and inhibits PD-L1 (CD274), potentially resulting in increased immune response to tumors (PMID: 25943534, PMID: 28214651). Imfinzi (durvalumab) is FDA approved for use in patients with urothelial carcinoma and unresectable, stage III non-small cell lung cancer, in combination with etoposide and carboplatin or cisplatin in patients with extensive stage small cell lung cancer, and in combination with cisplatin and gemcitabine in patients with locally advanced or metastatic biliary tract cancer (FDA.gov).|
|Etoposide||Vepesid||EPEG|Eposin|VP-16|VP-16-213||TOPO2 inhibitor 5||Vepesid (etoposide) binds to and inhibits DNA topoisomerase II, resulting in accumulated DNA damage, inhibition of replication, and cell death (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04745689||Phase II||AZD2811 + Durvalumab Cisplatin + Durvalumab + Etoposide Carboplatin + Durvalumab + Etoposide||Study of AZD2811 + Durvalumab in ES-SCLC (TAZMAN)||Active, not recruiting||USA | ESP||2|
|NCT04951115||Phase II||Cisplatin + Durvalumab + Etoposide Carboplatin + Durvalumab + Etoposide||A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Cell Lung Cancer||Recruiting||USA||0|
|NCT05403723||Phase I||Cisplatin + Durvalumab + Etoposide Carboplatin + Durvalumab + Etoposide||Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC||Not yet recruiting||USA||0|
|NCT04397003||Phase II||Carboplatin + Durvalumab + Etoposide Durvalumab + Tremelimumab Durvalumab + Personalized cancer vaccine + Tremelimumab||Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) and Tremelimumab in Extensive Stage Small Cell Lung Cancer||Recruiting||USA||0|
|NCT04774380||Phase III||Cisplatin + Durvalumab + Etoposide Carboplatin + Durvalumab + Etoposide||Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer (LUMINANCE)||Recruiting||ITA | DEU | CAN||3|
|NCT03963414||Phase I||Carboplatin + Durvalumab + Etoposide + Tremelimumab Carboplatin + Durvalumab + Etoposide||A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC||Terminated||USA||0|
|NCT05161533||Phase II||Cisplatin + Durvalumab + Etoposide Carboplatin + Durvalumab + Etoposide||Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial||Not yet recruiting||USA||0|